As of 9:44am ET
| -0.02 / -1.32%|
The 4 analysts offering 12-month price forecasts for Aviragen Therapeutics Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 2.50. The median estimate represents a +235.57% increase from the last price of 1.49.
The current consensus among 3 polled investment analysts is to Buy stock in Aviragen Therapeutics Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.